BHCM
ORIC icon

Brevan Howard Capital Management’s Oric Pharmaceuticals ORIC Stock Holding History

Brevan Howard Capital Management’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$250K Sell
19,709
-69,823
-78% -$793K ﹤0.01% 1759
2025
Q4 		$732K Buy
89,532
+40,437
+82% +$465K 0.01% 912
2025
Q3 		$589K Buy
49,095
+14,370
+41% +$151K ﹤0.01% 1198
2025
Q2 		$352K Buy
+34,725
New +$233K ﹤0.01% 1493

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Brevan Howard Capital Management's ORIC Position: Q1 2026 in Review

Brevan Howard Capital Management reduced its Oric Pharmaceuticals (ORIC) stake by 78% in Q1 2026, selling an estimated $793K and leaving 19,709 shares worth $250K. The position accounts for ﹤0.01% of the portfolio, ranked #1759.

Brevan Howard Capital Management first reported a position in ORIC in Q2 2025 and has held it in 4 quarters since. The position peaked at $732K in Q4 2025. 182 funds tracked by Wall St. Rank hold ORIC as of Q1 2026.

  • Brevan Howard Capital Management held 19,709 shares of Oric Pharmaceuticals worth $250K as of Q1 2026.
  • Brevan Howard Capital Management sold 69,823 Oric Pharmaceuticals shares in Q1 2026, an estimated $793K.
  • Oric Pharmaceuticals made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q1 2026, its #1759 holding.
  • Brevan Howard Capital Management first reported a position in Oric Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • Brevan Howard Capital Management's Oric Pharmaceuticals position peaked at $732K in Q4 2025.
  • 182 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.